patients were male with a mean HBsAg baseline of 388.4 IU/ml. The overall rate of HBsAg loss for patients treated ≥12, ≥24, ≥36 and ≥48 weeks was 13.00%, 16.06%, 20.49% and 23.01%. Subgroup analysis based on baseline HBsAg stratification (0.05–100, 100–500, 500– 1000, 1000–1500 IU/mL) found that the HBsAg loss rate was highest in patients with baseline HBsAg between 0.05 and 100 IU/mL (34.93% for patients treated ≥48 weeks). Fig 1: Interim data of HBsAg loss of Everest Project in China. *The mean baseline of HBsAg was 388.4 IU/ml. Conclusion: Functional cure can be well achieved in NA suppressed CHB patients by pegIFNα “add-on” or “switch to” strategies, especially for those with lower HBsAg baseline. Patients who complete the full course of treatment have the highest chance to functional cure. The rate of HBsAg loss in this large-scale real-world study is consistent with previous clinical research. SAT467 Occurence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment: a multicenter study in Taiwan Yi-Hsiang Huang 1,2 , Ming-Lung Yu 3,4 , Cheng-Yuan Peng 5 , Chun-Jen Liu 6,7 , Chao-Hung Hung 8 , Pin-Nan Cheng 9,10 , Jyh-Jou Chen 11 , Tsung-Hui Hu 12 , ChiehJu Lee 13 , Rong-Nan Chien 14,15 . 1 Taipei Veterans General Hospital, Taipei, Taiwan, Division of Gastroenterology and Hepatology, Department of Medicine, Taiwan; 2 National Yang-Ming University, Taipei, Taiwan, Institute of Clinical Medicine, Taiwan; 3 Kaohsiung Medical University Hospital, Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center , Taiwan; 4 Kaohsiung Medical University, Kaohsiung, Taiwan, Taiwan; 5 China Medical University Hospital, Taichung, Taiwan, Division of Hepatogastroenterology, Department of Internal Medicine, Taiwan; 6 National Taiwan University College of Medicine, Taipei, Taiwan, Graduate Institute of Clinical Medicine, Taiwan; 7 National Taiwan University Hospital, Taipei, Taiwan, Division of Gastroenterology and Hepatology, Taiwan; 8 ChiaYi Chang Gung Memorial Hospital, Chiayi, Taiwan, Division of Hepatogastroenterology, Department of Internal Medicine, Taiwan; 9 National Cheng Kung University Hospital, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taiwan; 10 National Cheng Kung University, Tainan, Taiwan, College of Medicine, Taiwan; 11 Chi-Mei Medical Center, Liouying, Tainan, Division of Gastroenterology and Hepatology, Taiwan; 12 Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, Division of Hepatogastroenterology, Department of Internal Medicine, Taiwan; 13 Taipei Veterans General Hospital, Taipei, Taiwan, Division of Gastroenterology and Hepatology, Department of Medicine, Taiwan; 14 Linkou Medical Center, Chang Gung Memorial Hospital, Taiwan, Division of Hepatology, Department of Gastroenterologyand Hepatology, Taiwan; 15 Keelung Medical Center, Chang Gung Memorial Hospital, Taiwan, Division of Hepatology, Department of Gastroenterology and Hepatology, Taiwan Email: yhhuang@vghtpe.gov.tw Background and Aims: Nucleos(t)ide analogues (NUCs) treatment, including entecavir (ETV) or tenofovir (TDF), had been demonstrated to reduce the risk of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). However, some studies reported an even lower risk of HCC occurrence by TDF as compared with ETV. We performed a multi-center study to compare the incidence of HCC between the two NUCs among lamivudine-naive CHB patients by collecting data from ten medical centers in Taiwan. Method: From 2007, 5131 CHB patients had been received ETV or TDF treatment in this multicenter data cohort. Among them, 816 patients were excluded due to HCV coinfection, underlying HCC or malig- nancy, less than 6 months of treatment, lamivudine-experienced or resistance. Finally, 4315 patients were recruited in this study, including 3124 on ETV and 1191 on TDF treatment. Factors associated with HCC occurrence were evaluated. Results: Of the 4315 patients,1106 had underlying liver cirrhosis. As of the end of 2018, 192 patients developed HCC, with the incidence of 0.009 per person-year for ETV and 0.008 per person-year for TDF. Factors associated with HCC occurrence were age >55 y/o (HR = 2.717, 95% CI = 2.017–3.661, p < 0.001), male gender (HR = 1.441, 95% CI = 1.029–2.017, p = 0.033), and presence of cirrhosis (HR = 5.705, 95% CI = 4.162–7.821, p < 0.001) in multivariate analysis. There was no statistical difference in the risk of HCC occurrence between ETV or TDF treatment. In subgroup patients with cirrhosis, the incidence of HCC was 0.021 per person-year for ETV, and 0.025 per person-year for TDF. Again, TDF, as compared with ETV, did not further reduce the risk of HCC in univariate analysis. Only male gender and age >55 y/o were the significant factors related to HCC development in cirrhotic patients. Conclusion: The statistical difference of the HCC risk between TDF and ETV was not reached in this multicenter, large cohort study, even in subgroup patients with liver cirrhosis. SAT468 Anti-HBS induction and HBsAg reduction by nasal administration of a therapeutic vaccine containing HBsAg and HBcAg (NASVAC) in patients with chronic HBV infection Osamu Yoshida 1 , Akbar Sheikh Mohammad Fazle 2 , Takahiro Sanada 3 , Michinori Kohara 3 , Kyoko Tsukiyama-Kohara 4 , Takashi Miyazaki 5 , Taizo Kamishita 5 , Mamun Al-Mahtab 6 , Aguilar Julio 7 , Gerardo Guillen 7 , Yoichi Hiasa 1 . 1 Ehime University Graduate School of Medicine, Department of Gastroenterologyand Metabology, Toon, Japan; 2 Ehime University Graduate School of Medicine, Department of Pathology , Toon, Japan; 3 Tokyo Metropolitan institute of Medical Science, Department of Microbiology and Cell Biology, Japan; 4 Kagoshima University, Joint Faculty of Veterinary Medicine, Kagoshima, Jersey; 5 TOKO YAKUHIN KOGYO CO., LTD, Osaka, Japan; 6 Bangabandhu Sheikh Mujib Medical University, Department of Hepatology, Dhaka, Bangladesh; 7 Center for Genetic Engineering and Biotechnology, Biomedical Research Department, Havana, Cuba Email: yoshidao@m.ehime-u.ac.jp Background and Aims: HBs antigen (HBsAg) loss is termed functional cure and recognized as an ideal treatment goal for the patients with chronic hepatitis B virus (HBV) infection. However, it is difficult to achieve functional cure by nucleos(t)ide analogs (NAs) or interferon. Thus NAs require long-term treatment. Further, chronic HBV infection without hepatitis, not recommended for anti-HBV therapy by current guidelines, needs suitable drugs for achieving functional cure, because these patients owe a risk for hepatic flare and hepatocellular carcinoma. This study was aimed to assess the efficacy of nasal administrative therapeutic vaccine, NASVAC, contain- ing both HBsAg and HBcAg, on kinetics of HBsAg in CHB patient under NAs and chronic HBV infection without hepatitis. Method: CHB patient with NAs and HBV carrier enrolled in an open- label clinical trial at Ehime University Hospital, Japan, after obtaining written consent and permission from institutional review board and enrollment of study to the clinical trial authority of Japan POSTER PRESENTATIONS S887 Journal of Hepatology 2020 vol. 73 | S653–S915